Dr. Miao Wang Joins AusperBio as Vice President of Clinical Development to Advance HBV Cure Candidate AHB-137

Jan 19, 2024 11:52 CST Updated 11:52

AusperBio

Biological Vaccine and Nucleic Acid Drug Developer

January 17, 2024 - AusperBio (Ausper Biopharma Co., Ltd. and AusperBio Therapeutics Inc.) announced:Dr. Miaowang joins AusperBio as Vice President of Clinical (VP) Position, responsible for clinical development affairs。

Dr. Wang Miao has nearly two decades of experience in clinical development of innovative drugs and outstanding team leadership. He has held key positions such as Medical Director or VP in listed pharmaceutical companies including North China Pharmaceutical, Staidson, Akeso Biopharma, and Livzon Pharmaceutical, focusing on therapeutic areas such as infectious diseases, autoimmune disorders, and neurologic/psychiatric conditions.Has successfully advanced multiple innovative drugs.

AusperBio CEO Dr. Guofeng Cheng stated: "Currently, AusperBioHBV Cure ASODrug AHB-137Has entered a crucial phase of clinical trials. Dr. Wang Miao's extensive experience in clinical development, comprehensive background in medical science, and profound understanding of drug research and development will greatly empower AusperBio.Domestic/International Clinical Trials, Accelerating AHB-137Clinical Progress of Phase II, III, and Other Innovative Drugs for AchievingAusperBio's Globalization Strategy Has Profound Significance."

Dr. Wang Miao stated："The outstanding leadership team, robust scientific platform, and exciting clinical progress of AusperBio have deeply moved me. I am truly honored to join AusperBio! Leveraging my years of experience in the clinical field and adhering to the firm belief of functionally curing hepatitis B, I will collaborate with the excellent team to accelerate bringing solutions to patients.Improve Life Health"Innovative drugs."

About AusperBio:

AusperBio is a clinical-stage innovative drug research and development company operating simultaneously in China and the United States, committed to developing First-in-class and Best-in-class self-innovative targeted delivery small nucleic acid drugs. AusperBio owns the proprietary intellectual property Med-Oligo™ ASO patent technology platform, focusing on functional cures for chronic hepatitis B (HBV) and highly efficient targeted treatments for liver diseases, while also expanding into therapies targeting new sites beyond the liver.. AusperBio's strategy is to leverage its leading Med-Oligo™OligonucleotideBy combining technology with specific and highly efficient targeting techniques, we can address a wide range of currently unmet medical needs.

E.N.D

In order to enable everyone to learn and communicate with each other more effectively,"WeChat Official Account 'Cell Gene Therapy' Team"A WeChat group for cell therapy and gene therapy has been established. Interested friends can scan the QR code below to add the editor's WeChat and join the cell therapy and gene therapy discussion group.。

Previous article recommendations:

Treg Cell Therapy Pioneer Completes Over 500 Million Yuan in Series A Financing

BeiGene Fined $400,000

Hengsai Biotech Completes Tens of Millions of Yuan in A+ Round Financing

Another Milestone! The World's First CRISPR-Based Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia

NewKer Subsidiary to Collaborate with Huadao Bio on CAR-T Drug Development

Lingyi Bio's Gaucher Disease AAV Gene Therapy Drug LY-M001 Approved for Clinical Trials

Official Announcement! FDA Releases 2023 New Drug Annual Report

Legend Biotech Shines at JPM, CAR-T Products Continue the Legend

Zou Jianjun Appointed as General Manager and Chief Executive Officer of Junshi Biosciences

$200 Million in Sales, the First DMD AAV Gene Therapy Drug Exceeds Expectations by a Wide Margin

Over 300 Million Yuan in Series A Financing to Advance AAV Gene Therapy for Alzheimer's Disease

Exosome Anti-Aging First Stock Listed, Market Value Exceeds 490 Million Yuan

Research Progress and Prospects of mRNA Tumor Vaccines

AusperBio Completes RMB 430 Million Series B Financing for ASO Therapy

$2 Billion! Johnson & Johnson Acquires Ambrx

Direct Delivery of Gene Therapy Drugs into the Brain: Innovative Parkinson's Disease Treatment Meets Primary Clinical Trial Endpoint

Behind the First Case of CAR-NK Therapy for Systemic Lupus Erythematosus at Shanghai Changhai Hospital

Gene Editing Start-up Acquires New Company for $185 Million

Top Ten Clinical Trials to Watch in the First Half of 2024

Yimiao神州GPC3 CAR-T Approved for Clinical Trials

Another AAV Gene Therapy Approved for Marketing

Co-Develop Ready-to-Use In Vitro and In Vivo Cell and Gene Therapies: IASO Bio and Umoja Biopharma Announce Further Deepening of Strategic Collaboration

Clinical Trial Results of China's First Bacterial Gene Therapy for PKU Announced

Disclaimer: The content is sourced from AusperBio. This article aims to share knowledge, and all content is for reference only, not constituting any advice.